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Abstract: Brains that are affected by Alzheimer’s disease (AD) are characterized by the overload of
extracellular amyloidβ (Aβ) peptides, but recent data from cellular and animal models propose that Aβ
deposition is preceded by intraneuronal accumulation of the direct precursor of Aβ, C99. These studies
indicate that C99 accumulation firstly occurs within endosomal and lysosomal compartments and that
it contributes to early-stage AD-related endosomal-lysosomal-autophagic defects. Our previous work
also suggests that C99 accumulation itself could be a consequence of defective lysosomal-autophagic
degradation. Thus, in the present study, we analyzed the influence of the overexpression of the
transcription factor EB (TFEB), a master regulator of autophagy and lysosome biogenesis, on C99
accumulation occurring in both AD cellular models and in the triple-transgenic mouse model
(3xTgAD). In the in vivo experiments, TFEB overexpression was induced via adeno-associated viruses
(AAVs), which were injected either into the cerebral ventricles of newborn mice or administrated
at later stages (3 months of age) by stereotaxic injection into the subiculum. In both cells and the
3xTgAD mouse model, exogenous TFEB strongly reduced C99 load and concomitantly increased
the levels of many lysosomal and autophagic proteins, including cathepsins, key proteases involved
in C99 degradation. Our data indicate that TFEB activation is a relevant strategy to prevent the
accumulation of this early neurotoxic catabolite.
Keywords: Alzheimer’s disease; C99; βCTF; TFEB; 3xTgAD mice; AAV8; cathepsins; lysosomes
1. Introduction
Alzheimer’s disease (AD) is the most common form of neurodegenerative dementia and has
been mainly associated with the accumulation of extracellular plaques composed of aggregated
Aβ and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. Aβ is
derived from the amyloid precursor protein (APP) by sequential proteolytic processing by β- and
γ-secretases [1]. The initial cleavage of APP by β-secretase results in the secretion of the soluble
ectodomain sAPPβ and the generation of a membrane-tethered C-terminal fragment C99 (or βCTF) that
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is cleaved by γ-secretase to form Aβ. Increasing evidence indicates that Aβ accumulation is preceded by
intraneuronal accumulation of C99, which contributes to AD pathology by affecting the endolysosomal
network [2–11]. Firstly, in brain fibroblasts derived from Down’s syndrome (DS) patients, a disorder in
which patients develop an early form of AD likely due to a third copy of APP present on chromosome
21 [12], C99 accumulation was found to cause enlargement of Rab5-positive early endosomes [2–4].
Strikingly, these alterations resembled those described years before in post-mortem brains from
early-stage AD-affected patients [13]. Later on, it was shown that C99 accumulation also induces
lysosomal-autophagic pathology in both cellular and animal AD models [5,6,8,10]. Importantly, both
of these C99-induced defects are also observed in human iPSC (induced pluripotent stem cell) neurons
carrying endogenous levels of familial APP or PSEN1 mutations, indicating that these alterations occur
in the absence of overexpressed APP [8,9]. For instance, late endosomal and lysosomal pathologies
were observed in monogenic iPSCs derived from AD patients carrying APP or PSEN1 mutations [8]
and early endosome defects were demonstrated in isogenic APP and PSEN1 mutant iPSCs generated
by CRISPR/Cas9 knock-in [9]. Interestingly, in all these reports, alterations were mediated by C99
itself and not by Aβ, since the pharmacological inhibition of the β-secretase BACE1 (that prevents
formation of both C99 and thereby Aβ) abrogated these defects, whereas they were amplified by
the blockade of γ-secretase (that halts Aβ generation and thus enhances C99 levels). Moreover,
recent studies showed that these C99-induced endosomal alterations are associated with aberrant
neurotrophic signaling and cholinergic neurodegeneration [7], brain network alterations, and neuronal
hyperactivity [14], as well as with long-term potentiation deficits and cognitive impairment [6,15,16].
In addition, a recent study using brain tissue sections from sporadic AD-affected brains showed
both an anatomical and quantitative correlation of C99, but not of Aβ, with the degree of neuronal
vulnerability to neurodegeneration and cognitive impairment [17]. Overall, these reports consistently
document a key role of C99 accumulation in AD pathogenesis and thus suggest that the inhibition of
early AD-associated C99 accumulation should be beneficial [18].
Our recent studies suggest that C99 accumulation in the 3xTgAD mouse model is linked to a
defective lysosomal degradation rather than to a lowered γ-secretase-mediated processing [6]. Thus,
2xTgAD mice (expressing wild-type presenilin) display similar C99 accumulation than 3xTgAD mice,
although the levels of Aβ are barely detectable in the former model, indicating that C99 accumulation
could not be directly due to reduced γ-secretase activity. Indeed, C99, as other APP-CTFs are known
to be degraded by cathepsins through the lysosomal-autophagic degradation pathway [6,19–21], but
lysosomal degradation is defective in AD [22]. The basic helix-loop-helix leucine zipper transcription
factor EB (TFEB) is a master regulator of lysosome and autophagy biogenesis [23]. Under physiological
conditions, TFEB undergoes mTOR-mediated phosphorylation and resides in the cytosol. Under
aberrant lysosomal storage conditions, TFEB is dephosphorylated and, consequently, is translocated
into the nucleus where it activates its target genes via the CLEAR (Coordinated Lysosomal Expression
and Regulation) consensus sequence. As opposed to autophagic activators, TFEB promotes cellular
clearance by regulating several steps of lysosomal-autophagic degradation including lysosome
biogenesis, autophagosome formation, and autophagosome-lysosome fusion [23]. Indeed, TFEB
is known to upregulate more than 290 genes including cathepsins, the main proteases involved
in lysosomal APP-CTF degradation [6,20]. A still increasing amount of literature shows that both
exogenous expression of TFEB and pharmacological activation of endogenous TFEB can promote the
selective clearance of intracellular neurotoxic proteins and can have beneficial effects in these diseases
(for review see [24,25]). Thus, we aimed at investigating the potential of TFEB overexpression to
lower C99 expression in AD cellular models as well as a mean to interfere with early intraneuronal
accumulation in vivo, in the 3xTgAD mouse model.
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2. Materials and Methods
2.1. Animals and Viral Infection
3xTgAD mice (harboring APPswe, PS1M146V, and TauP301L transgenes) [26] were generated from
breeding pairs provided by Dr. La Ferla (Irvine, CA, USA). AAV8 viral particles (generated by the Hope
Center Viral Core at Washington University) driving expression of TFEB (AAV8-cmv-FLAG-TFEB)
or GFP (AAV8-cmv-GFP) (2.8 × 1012 vg/mL (viral genomes per mL)) [27] were delivered in vivo by
means of two distinct protocols. In the first protocol, AAVs were injected into the ventricles of newborn
mouse brains as described previously [6,28]. Briefly, newborn (post-natal day 0, P0) females were
injected unilaterally into ventricles with 2.5 µL of AAV8-cmv-FLAG-TFEB (n > 30) or AAV8-cmv-GFP
(n > 30) and mice were analyzed at 8 months post-AAV delivery. In the second protocol, AAVs were
delivered by stereotaxic injection into the subiculum of 3-month-old females (n = 8). Mice were
anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (24 mg/kg) and placed
in a stereotaxic apparatus. Viruses (2 µL per site) were then injected bilaterally into the subiculum
at the following coordinates from bregma AP, −3.8, ML, 2.5, and DV, 1.5 at a flowrate of 0,4 µL/min.
Animals were euthanized 5 months post-injection, e.g., at 8 months of age. For immunohistochemistry,
mice were anesthetized as described above and intracardiacally perfused with PBS followed by 4%
paraformaldehyde before collecting the brains. All animals were housed with a 12:12 h light/dark cycle
and were given free access to food and water and experimental procedures were in accordance with
the European Communities Council Directive of 24 November 1986 (86/609/EEC) and approved by
Nice University Animal care and use Committee, and the National Council on Animal care of the
Ministry of Health (Project Number: APAFiS#17993-2018112613266973 v2).
2.2. Cell Culture and Treatments
Human neuroblastoma overexpressing Swedish mutated APP (SH-SY5Y-APPswe) [29], or human
embryonic kidney cells (HEK293, ATCC), naïve or stably overexpressing APPswe (HEK-APPswe) [30]
or C99 (HEK-C99) [31]), were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum, penicillin (100 U/mL), and streptomycin (50µg/mL) purchased from Life Technologies
(Villebon sur Yvette, France) and with G418 or puromycin, respectively, for stable lines at 37 ◦C/5%
CO2. One day before transfection, cells were either plated into 6-well plates (biochemical studies) or
were plated into poly-D-lysine coated coverslips placed in 12-well plates (for immunocytochemistry).
Transient transfections of cells were carried out using lipofectamine 2000 (Life Technologies) for
SH-SY5Y and JetPrime (Polyplus transfection, Ozyme, Montigny le Bretonneux, France) for HEK293
cells, according to the manufacturer’s instructions, and cells were recovered 48 h post-transfection.
SH-SY5Y-APPswe and HEK-APPswe were transfected with FLAG-tagged murine TFEB cDNA or the
empty pAAV vector containing a CMV promoter [27], whereas naïve HEK cells were co-transfected
with C99 and TFEB cDNA (or empty vector).
2.3. Immunolabeling of Tissue and Cultured Cells
Paraformaldehyde-fixed brains (see above) were embedded in paraffin and cut on a microtome in
8 µm thick sections (Thermoscientific, Illkirch, France). Brain sections were treated with formic acid for
5 min followed by heat treatment in citrate buffer during 30 min. After saturation in 5% BSA/0.1%
Triton, slices were incubated at 4 ◦C overnight with primary antibodies (α-TFEB (rabbit polyclonal,
Bethyl 1:1000), α-CatB (rabbit monoclonal, Abcam 1:1000), α-CatD (rabbit monoclonal, Abcam 1:1000),
α-NeuN (rabbit monoclonal, Abcam 1:2000), α-Tuj1 (mouse monoclonal, BioLegend, 1:1000), 82E1
(mouse monoclonal, IBL 1:200), α-APPct (rabbit polyclonal, gift from Dr Fraser, 1:1000)) followed
by HRP-conjugated antibodies (Jackson ImmunoResearch, 1:1000) and DAB substrate (DAB impact,
Vector LAbs), Alexa Fluor-488 or Alexa Fluor-647 conjugated anti-mouse or anti-rabbit antibodies
(Molecular Probes, 1:1000) and DAPI (Roche, 1:20 000). Other slices were used for the 4-color IHC
Opal Multiplex assay (Perkin Elmer, Villebon sur Yvette, France) allowing highly sensitive protein
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detection using primary antibodies from the same species. Slices were pretreated as described above,
incubated sequentially with primary antibodies for 1 h at room temperature and secondary antibodies
from the OPAL kit (1/1000) and stripped at 95 ◦C in citrate buffer for 20 min. When using the OPAL
assay, it was possible to label TFEB, cathepsin B, or cathepsin D as well as C-termini of APPct on the
same slices. Cells in culture were fixed with paraformaldehyde, permeabilized with 0.1% Triton-X
100 for 10 min, saturated in 5% BSA/0.1% Triton-X 100, probed 1 h with primary antibodies (for TFEB
detection with α-TFEB (Bethyl 1:5000) or α-Flag (Sigma 1:5000) and for APP-CTF detection with
α-APPct, (1:5000), 6E10 (Covance, 1:1000) or 82E1 (IBL, 1:1000)) followed by Alexa Fluor-488 and Alexa
Fluor-594 conjugated antibodies (Molecular Probes, 1:1000) and DAPI (1:20,000) staining. Confocal
images were acquired using a Zeiss SP5 confocal (Marly le Roi, France) or an Olympus Fluoview10
microscope (Rungis, France) for cells and an Olympus Fluoview10 confocal microscope for tissue
sections. Images of tissue sections revealed with the DAB substrate were photographed using a bright
field microscope (DMD108, Leica, Paris, France,).
2.4. Immunofluorescence Quantification
SH-SY5Y-APPswe cells were transfected with FLAG-tagged murine TFEB cDNA or the empty
pAAV vector containing a CMV promoter [27] and immunolabeled at 48 h post-transfection with
α-Flag (for TFEB detection) and α-APPct (for APP-CTF detection). Images were acquired randomly
using an Olympus Fluoview10 microscope (Rungis, France) and an objective 40×. A total of 6–7 images
(about 100 cells each) were acquired for each condition (in 3 independent experiments). Quantification
of the intensity of APP-CTF immunolabeling was performed using a home-made quantification
program allowing the detection of the total number of cells (visualized with DAPI nuclei, blue staining),
TFEB-positive cells (green labeling), and APPct immunoreactivity (red staining). The quantification of
APPct staining intensity was compared in TFEB-positive (green) versus TFEB-negative (blue but not
green) cells. In the in vivo experiments, 82E1 immunostaining was estimated by a visual inspection of
TFEB-positive neurons (in stereotaxic-injected mice, n = 250 cells) and staining was determined as
being absent, low or normal (as compared to that of the surrounding TFEB-negative neurons).
2.5. Western Blot Analysis
Cell homogenates (20–40 µg) were separated by Bio-Rad 12% stain-freeTM TGX FastCastTM
acrylamide gels or 16% tris-tricine gels (for the detection of APP-CTFs). Bio-Rad gels were
photoactivated for the visualization of proteins before being electrophoretically transferred to
nitrocellulose membranes using the Bio-Rad Trans-Blot® TurboTM Transfer System. Tris-tricine gels
were directly transferred to nitrocellulose membranes using a conventional transfer system and boiled
in PBS before saturation with skimmed milk. Membranes were blotted with the following antibodies:
α-APPct (1:1000), α-FLAG (1:5000), α-TFEB (1:1000), α-CatD (1:1000), α-LC3 (Novus. 1:1000), orα-Actin
(Sigma, 1:5000). After probing with primary antibodies, immunological complexes were revealed with
HRP-conjugated antibodies (Jackson ImmunoResearch, 1:10,000) followed by electrochemiluminescence
(WesternbrightTM SiriusTM and QuantumTM chemiluminescent HRP substrate, Advansta, France).
Peak height of signal intensities from protein bands were quantified with ImageJ software.
2.6. mRNA Extraction and Quantitative RT-PCR
Hippocampal tissue was lysed using magnetic beads and the MagNA lyser (Roche, Meylan,
France). RNA from hippocampal tissue or cells was isolated using RNeasy Plus-Universal kit and
RNeasy mini kit (Qiagen, Les Ulis, France), respectively. cDNAs were synthesized from 2 µg total
RNA using AMV reverse transcriptase (Promega, GoScript) and oligo-dT primers. Then, samples were
subjected to real-time PCR by means of a Rotor-Gene 6000 apparatus (Qiagen, Les Ulis, France), using
the SYBR Green Roche detection protocol. Gene-specific primers (Table 1) were designed with the
Universal Probe Library Assay Design Center software (Roche Applied Science, France). Relative
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expression analysis was normalized against two reference genes, the ribosomal gene RPL19 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (see Table 1), which were amplified in parallel.
Table 1. List of primers used for quantitative RT-PCR.























All quantitative data were subjected to non-parametric tests, the Mann–Whitney U test for single
comparison using GraphPad Prism 7. Data are represented as means ± SEM. Statistical significances
were set up as * p < 0.05, ** p< 0.01 and *** p < 0.001.
3. Results
3.1. TFEB Overexpression Reduces APP-CTF Levels in both APPswe and C99 Expressing Cells
In order to determine the effects of TFEB overexpression on APP-CTF levels, we first transfected
SH-SY5Y-APPswe cells with TFEB cDNA or an empty vector (Figure 1). Immunoblot analysis revealed
that TFEB protein expression was higher in cell homogenates at 24 h than at 48 h post-transfection,
(Figure 1A), while TFEB-mediated transcriptional effects peaked 48 h after transfection, as observed
for cathepsin B (Figure 1A), suggesting a time-dependent shifting between TFEB protein expression
and transcriptional function. Accordingly, quantitative PCR aimed at analyzing the effects of TFEB
overexpression on TFEB-induced lysosomal and autophagic genes [23] was performed at 48 h
post-transfection. In SH-SY5Y-APPswe neuroblastoma, TFEB induced an upregulation of several
lysosomal and autophagic mRNAs (Figure 1B), but interestingly, it had strong effects on the expression
of cathepsin mRNAs and particularly on that of CTSD encoding cathepsin D, one of the main proteases
involved in C99 degradation. As previously described, TFEB also enhanced the transcriptional
expression of the lysosomal membrane proteins LAMP1 and LAMP2B and of the autophagic genes
MAP1LC3B (LC3) and SQSTM1 (p62) (Figure 1B). TFEB overexpression did not affect APP mRNA
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expression (Figure 1B). These findings were in agreement with immunocytochemical analysis revealing
that overexpression of TFEB (detected by either α-FLAG (Figure 1C) or α-TFEB (Figure 1F)) was
sufficient to activate it, e.g., to drive it into the nucleus to activate the transcription of cognate genes,
as we have previously described [27]. Next, to assess the influence of TFEB expression on APP and
APP-CTFs, we performed co-immunostaining using α-FLAG and α-APPct (Figure 1C). Strikingly, cells
devoid of TFEB displayed strong α-APPct immunoreactivity whereas this immunostaining was barely
detectable in TFEB-positive cells (Figure 1C). Indeed, the quantification of α-APPct immunoreactivity
revealed about 80% reduction in TFEB-positive cells as compared to TFEB-negative cells (Figure 1D).
This TFEB-mediated effect was also observed when immunocytochemical analysis was performed by
means of the N-terminal directed antibodies 82E1 and 6E10 (Figure 1D). To more precisely quantify
these effects on C99 levels, we switched into HEK293 cells to obtain higher gene transfection efficiency
and performed qPCR and immunoblot analysis (Figure 2). Indeed, in HEK293 cells TFEB gene
expression was 10 times higher than in SH-SY5Y cells. qPCR analysis indicated that TFEB triggered the
induction of lysosomal and autophagic gene expressions mostly similarly in HEK293 and SY-SY5Y cells
(Figure 2A) with the noticeable exception of CSTB mRNA levels that, unlike in SH-SY5Y cells, remained
unaffected in HEK293 cells. Thus, although comparison of TFEB-mediated phenotypes unraveled
some cell-specific transcriptional modulations, it was important to note that the APP-CTF-degrading
CSTD mRNA was strongly upregulated in both cell lines, indicating that HEK293 cells were a relevant
model to study TFEB-mediated regulation of APP-CTF expressions. In this context, we combined
three complementary cell models: first, a monoclonal HEK293 cell-line stably expressing APPswe [30]
and second, an inducible polyclonal HEK293 cell-line stably expressing C99 [31], two cell-lines which
were both transfected with TFEB or empty vector (Figure 2B–E). Third, naïve HEK293 cells were
co-transfected with C99 and TFEB cDNA (or empty vector) (Figure 2F,G). Whatever the cellular
model examined, TFEB overexpression consistently led to increased levels of cathepsin D and LC3
(Figure 2B,D,F) and more interestingly, TFEB overexpression also triggered a significant reduction
in both C99 and C83 levels in all models in accordance with the immunocytochemical analysis
(Figure 2B–G). Moreover, while TFEB had little if any effect on the levels of immature APP, it also
significantly reduced those of both overexpressed (Figure 2B,C) and endogenous (Figure 2F,G) mature
APP, as we previously observed [27].
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of lysosomal-autophagic gene products and to reduced C99 levels. Statistical differences were * p < 
0.05, ** p < 0.01, *** p < 0.001, ns = non significant (p > 0.05), versus control cells (empty) according to 
the Mann–Whitney test. (A) Immunoblot analysis revealed the levels of overexpressed TFEB and 
endogenous cathepsin B at 24 h or 48 h post-transfection. TFEB is detected using α-FLAG. (B) qPCR 
analysis of TFEB-mediated gene transcription showed the induction of numerous lysosomal-
autophagic genes. Gene expressions were normalized to the expression of the housekeeping gene 
RPL19 and represented in each case relatively to mock-transfected cells (C) SH-APPswe cells were 
transfected with TFEB cDNA and immunostained at 48 h post-transfection with α-FLAG (for TFEB 
detection) and α-APPct. Nuclei were stained with DAPI. (D) Quantification of α-APPct staining in 
TFEB-positive versus TFEB-negative cells. (E) Illustration of epitope recognition by the different 
Figure 1. Transcription factor EB (TFEB) overexpression in SH-SY5Y-APPswe cells leads to induction of
lysosomal-autophagic gene products and to reduced C99 levels. Statistical differences were * p < 0.05,
** p < 0.01, *** p < 0.001, ns = non significant (p > 0.05), versus control cells (empty) according to
the Mann–Whitney test. (A) Immunoblot analysis revealed the levels of overexpressed TFEB and
endogenous cathepsin B at 24 h or 48 h post-transfection. TFEB is detected using α-FLAG. (B) qPCR
analysis of TFEB-mediated gene transcription showed the induction of numerous lysosomal-autophagic
genes. Gene expressions were normalized to the expression of the housekeeping gene RPL19 and
represented in each case relatively to mock-transfected cells (C) SH-APPswe cells were transfected
with TFEB cDNA and immunostained at 48 h post-transfection with α-FLAG (for TFEB detection) and
α-APPct. Nuclei were stained with DAPI. (D) Quantification ofα-APPct staining in TFEB-positive versus
TFEB-negative cells. (E) Illustration of epitope recognition by the different antibodies. (F) SH-APPswe
cells were immunostained with α-TFEB (green labeling) and either 82E1 or 6E10 (red labelings).
Bar scale: 10 µm.
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numerous lysosomal-autophagic genes and to reduced C99 levels. (A) Bars show the quantification 
of qPCR analysis of TFEB-mediated gene transcription in naïve HEK-293-APPswe cells. (B–G) 
Immunoblot analysis of TFEB-mediated effects on lysosomal activation (cathepsin D and LC3 
immunoreactivities) and APP/APP-CTF levels in HEK-293 cells stably expressing APPswe (B and C) 
or C99 (D and E), or in naïve HEK-293 cells transiently transfected with C99 and TFEB cDNA or empty 
vector (F and G). Bars in (C, E and G) correspond to the quantification of APP-CTFs, APPfl, LC3 and 
CatD (n = 12 from at least 3 independent determinations in each cell line) and are represented as 
Figure 2. TFEB overexpression in HEK-293 APPswe or C99 expressing cells leads to the induction of
numerous lysosomal-autophagic genes and to reduced C99 levels. (A) Bars show the quantification of
qPCR analysis of TFEB-mediated gene transcription in naïve HEK-293-APPswe cells. (B–G) Immunoblot
analysis of TFEB-mediated effects on lysosomal activation (cathepsin D and LC3 immunoreactivities)
and APP/APP-CTF levels in HEK-293 cells stably expressing APPswe (B,C) or C99 (D,E), or in naïve
HEK-293 cells transiently transfected with C99 and TFEB cDNA or empty vector (F,G). Bars in (C,E,G)
correspond to the quantification of APP-CTFs, APPfl, LC3 a d C tD (n = 12 from at least 3 independent
determinations in each cell line) and are represented as means ± SEM and are expressed as the percent
of control transfected cells (taken as 100). Statistical differences were * p < 0.05, ** p < 0.01, *** p < 0.001,
ns = non significant (p > 0.05), versus control (empty) cells according to the Mann–Whitney test.
3.2. TFEB Overexpression Lowers C99 Accumulation in the Triple-Transgenic Mouse Model
Our previous works have proposed that C99 accumulation in the 3xTgAD is a consequence
of defective lysosomal-autophagic degradation rather than a defective γ-secretase processing [6].
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Although these data revealed increased levels of both autophagic and lysosomal proteins including
cathepsins, in the 3xTgAD mouse, as compared to non-transgenic mice, we found a decrease in
lysosomal function when estimated by cathepsin (B and D) enzymatic dosages. Here, in order
to evaluate the functional status of TFEB in these mice, we performed qPCR measurements of
some of the TFEB regulated genes (Supplementary Figure S1A). This analysis revealed a significant
upregulation of TFEB itself, as well as of CSTB and CSTD mRNAs, in 3xTgAD mouse hippocampi as
compared to age-matched controls. These data propose that TFEB signaling is upregulated, rather than
downregulated in these mice. Thus, we investigated the potential of TFEB overexpression to reduce this
C99 accumulation. For that purpose, we used two distinct strategies based on viral-mediated delivery
of TFEB by means of AAV8-cmv-FLAG-TFEB [27], which were administrated into mice at different
stages: at birth or at 3 months of age, the latter corresponding to an age at which C99 accumulation
has started. In the first protocol, AAV8-cmv-FLAG-TFEB or control AAV8-cmv-GFP were delivered
into the cerebral ventricles of neonatal 3xTgAD mouse brains. This technique is described to ensure
widespread and long-lasting protein expression throughout the whole brain [32] and is routinely
used in our own laboratory for injecting AAV-10 particles [6]. Previous work has shown a critical
role of the timing of AAV injection, since it will determine both the biodistribution and tropism of
the gene product [32]. Indeed, it was observed that when injected in newborns older than about
24–48 h, AAV8 particles have a lower degree of diffusion and a preference for glial transduction [32].
Indeed, we confirmed these observations and found that AAV8-cmv-GFP injected into mice older
than 24 h (P1) mostly exhibit glial GFP expression, whereas the same viruses injected in younger
mice (less than 24 h after birth, P0), display almost exclusive neuronal expression, as visualized by
morphology inspection of 3-week-old mice (Supplementary Figure S1B). In these mice GFP expression
was observed throughout the brain including in the subiculum, the area displaying C99 accumulation
in the 3xTgAD mouse model [11]. Thus, in our experiments AAV8-cmv-FLAG-TFEB or control
AAV8-cmv-GFP were injected only at P0 in order to ensure neuronal expression. Then mice were
analyzed by immunohistochemistry at 8 months post-AAV-delivery, an age at which intraneuronal
staining with 82E1 still corresponds mostly to C99 [11]. Noticeably, while all animals displayed high
GFP expression within the subiculum, a much fewer number of animals displayed significant TFEB
expression within this area, although a similar number of viral particles were injected. Although in
most animals, TFEB expression was low in the subiculum, its expression was high in other brain areas,
suggesting a lower diffusion capacity, rather than a lower stability, of the TFEB viruses as compared to
the GFP viruses (not shown). Moreover, and in agreement with this hypothesis, the same differences
were observed when animals were analyzed at much earlier timepoints. However, as observed for
GFP, in these “TFEB-positive” animals, nearly all TFEB-positive cells were neurons as observed by
colocalization with the neuronal marker NeuN (Figure 3A). Moreover, high magnification images
indicated that many neurons display nuclear TFEB as observed with DAPI staining (Figure 3A, right
panels). Thus, we selected the cohort of animals displaying significant TFEB expression within the
subiculum to follow lysosomal activation and monitor C99 accumulation. C99 detection on paraffin
sections requires formic acid treatment [11] and we noticed that this treatment led to a complete
depletion of GFP-associated fluorescence in AAV-cmv-GFP animals probably due to formic acid
induced membrane permeabilization. This observation, however, allowed us to use green-fluorescence
conjugated antibodies for the detection of other proteins. To determine the effect of TFEB on lysosomal
activation, we performed immunohistochemistry with α-cathepsin B antibodies on slices adjacent to
those labeled with α-TFEB. In the animals expressing the highest levels of TFEB (n = 4), we observed
a clear increase in cathepsin B staining (Figure 3B, middle panel) within the same areas positive for
TFEB (Figure 3B, upper panel). Moreover, in these animals, co-immunostaining of TFEB and 82E1
revealed a strong reduction in 82E1-immunostaining, then indicating a decrease in C99 levels (Figure 3,
lower panels). In all other analyzed animals (n > 20), the expression of TFEB was too low within the
subiculum to induce both changes in cathepsin and C99 staining, indicating that these changes were
dependent on a high level of TFEB overexpression.
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with increased cathepsin expression a d a decrease i 99 accumulation. Mice were injected at P0
and analyzed by immunohistochemistry at 8 months of age. (A) Left panels show co-immunostaining
of TFEB (detected with α-TFEB, green) and the neuronal marker NeuN (red). Right panels show
nuclear localization of TFEB as colocalized with DAPI. (B) Images illustrate low and high magnification
co-immunostaining of TFEB (α-TFEB, green) and C99 (82E1, red) in AAV-cmv-GFP (left panels) and
AAV-cmv-FLAG-TFEB (right panels) mice. Lower panels show merged images of TFEB and 82E1.
Middle panels show cathepsin B immunostaining, which was performed on adjacent brain slides.
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In the second protocol, AAV8s were injected stereotaxically and bilaterally into the subiculum of
3-month-old animals, an age at which C99 can be consistently detected [11] (Figures 4 and 5). Here
again, immunohistochemical analysis was performed at 8 months of age. First, this analysis confirmed a
strong and widespread expression of TFEB in the subiculum. Unlike what was observed in icv-injected
newborn mice, TFEB was expressed in all injected mice and within almost the entire subiculum (n = 8)
(Figure 4A). Again, higher magnification images of the subiculum showed that TFEB overexpression
enhanced its nuclear localization i.e., activation. Both the morphological shape of TFEB-positive cells
and co-labeling with NeuN or Tuj1 (Figure 4B) indicated that most of these cells indeed corresponded
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to neurons. Here again, the comparison of AAVcmv-GFP and AAV-cmv-FLAG-TFEB-injected animals
indicated that the overexpression of TFEB strongly reduced C99 accumulation, as visualized both by
both HRP-conjugated antibodies and DAB development (Figure 5A) and after co-immunostaining
of TFEB and C99 and protein visualization with fluorescent-conjugated antibodies (Figure 5B,C). In
both cases, C99 staining was clearly reduced in TFEB-positive mice. High magnification images of
co-immunostaining of TFEB and 82E1 indicated that only TFEB-positive neurons displayed reduced
82E1 immunoreactivity (see arrows in Figure 5C), whereas in the same areas, TFEB-negative neurons
still displayed 82E1 staining. To obtain a more quantitative estimation of this TFEB-mediated effect,
we evaluated the 82E1 staining in TFEB positive cells, and found a total absence of staining in nearly
90% of TFEB-positive cells and a reduced staining in about 10% of the remaining TFEB-positive cells,
as compared to the staining in the surrounding neurons. A strongly reduced immunostaining in
TFEB-positive neurons were also seen when using α-APPct (Figure 5C).C lls 2020, 9, x FOR PEER REVIEW 12 of 18 
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Figure 5. The overexpression of TFEB after stereotaxic injection of AAVs in the subiculum of 3-month-old
3xTgAD mice leads to decreased C99 levels. Mice were analyzed by immunostaining at 8 months of age.
(A) Low- and high-magnification images illustrating the staining of 82E1 revealed with HRP-conjugated
antibodies and DAB in an AAV-cmv-GFP or AAV-cmv-FLAG-TFEB injected mouse at the level of the
subiculum. (B) Images of immunostaining of TFEB (red) and 82E1 (green) in 3xTgAD mice injected
with either AAV-TFEB or AAV-GFP at the level of the subiculum. (C) High-magnification images
revealing decreased 82E1 and α-APP-ct immunostaining within TFEB positive neurons (arrows). Scale
bar: 500 µm), 100 µm and 25 µm in (A) and 100 µm and 20 µm in (B).
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4. Discussion
Lysosomal-autophagic dysfunction is known to be a frequent feature of AD, which precedes
the classical late-stage hallmarks Aβ plaques and neurofibrillary tangles [22]. The transcription
factor EB (TFEB) is one of the key regulators of lysosomal-autophagic function [23]. TFEB regulates
both lysosomal biogenesis and autophagy by coordinating the expression of lysosomal hydrolases,
lysosomal membrane proteins, as well as autophagy-related genes in responses to lysosomal stress
conditions. Numerous studies suggest that the lysosomal-autophagic dysfunction in AD is related to a
defective TFEB function and, accordingly, propose TFEB activation as a possible strategy to counteract
disease progression in this pathology. However, contrasting findings regarding the TFEB status in AD
brain tissue have been reported. One study reported that TFEB is retained within the cytoplasm and
lowered in nuclear fractions of hippocampi from late-stage Braak AD brains [33], leading to reduced
TFEB-mediated activation of the CLEAR network. A similar situation was described in Parkinson’s
disease, in which α-synuclein acts as a sequestering molecule and impedes the translocation of TFEB
to the nucleus [34]. There are no evidences of similar effects on TFEB sequestering by aggregate-prone
proteins in AD, but other mechanisms leading to TFEB dysfunction have been proposed. One
study demonstrated that TFEB function is dependent on presenilin 1 and is negatively impacted by
AD-associated PSEN1 mutations, a mechanism which may explain TFEB dysfunction at least in some
familial AD cases [35]. Another study showed that apolipoprotein E4, the main AD susceptibility
risk factor [36], binds to the CLEAR motif and competes with TFEB binding, thereby suppressing
autophagy activation in apolipoprotein (APOE) e4/e4 carriers [37]. In contrast to these studies, others
have reported a gain of TFEB activity in AD. For instance, microarray analysis of CA1 neurons from
AD patients revealed an up-regulation of a high number of autophagic genes regulated by TFEB [38].
Moreover, immunohistochemistry showed a higher number of cells displaying nuclear TFEB [38] in
pathological brains. Similar up-regulation of autophagic genes was observed in transcriptomic analysis
of brain of the 5xFAD mouse model [39]. These apparently discrepant observations could well be
reconciled if one envisions a bell-shaped expression and/or function of TFEB in pathological conditions.
Thus, early activation of TFEB could be seen as an initial neuroprotective response to cell stress aimed at
circumscribing early accumulation of aggregated proteins, but which ultimately becomes functionally
disrupted or not sufficient to counteract protein accumulation. In the present study, we observed that
in the 3xTgAD mouse model many neurons displayed nuclear TFEB (at least when overexpressed,
since we were unable to detect endogenous TFEB, in agreement with a previous paper indicating
low endogenous TFEB levels in neurons [38]). Moreover, when we compared the endogenous gene
expression in age-matched non-transgenic and 3xTgAD hippocampi by qPCR measurements, we found
an increase in many TFEB targeted genes including CSTB, CSTD and LAMP1, as well as in TFEB itself
(suppl. Figure 1A) in the 3xTgAD model, which would then be in favor with upregulated rather than
downregulated TFEB signaling, although we cannot exclude the involvement of the other members
of the Mit/TFE3 family in this regulation [38]. Nevertheless, our previous works have indicated
defects in cathepsin function and substrate degradation, suggesting that, as hypothesized above, this
up-regulation of TFEB signaling could be seen as a compensatory mechanism, which however in
the 3xTgAD mouse is not sufficient to circumscribe protein accumulation and prevent a pathological
process [6].
Although it remains unclear to what extend TFEB function is defective in AD, previous studies
from AD cell and mouse models indicate that both the pharmacological and genetic activation of
TFEB could have beneficial effects. The first beneficial effect of TFEB overexpression on Aβ-related
pathology was observed after TFEB-mediated stimulation of astrocytic Aβ degradation in the APP/PS1
mouse [40]. Another work, using an in vitro model of brain slices derived from APP/PS1 mouse
brains, demonstrated that microglial expression of TFEB facilitated fibrillar Aβ degradation, an effect
that was found to be further enhanced by deacetylation of TFEB by Sirt1 [41]. Moreover, neuronal
overexpression of TFEB was found to reduce Aβ levels, an effect which was proposed to be due
to an enhanced lysosomal degradation of endocytosed APP [27]. In the present work, we used
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AAV8-cmv-TFEB particles [27] to investigate the efficiency of TFEB in reducing C99 accumulation
in the 3xTgAD mouse model, a model displaying early and consistent C99 accumulation in the
absence of detectable Aβ [11]. Our previous studies suggested that this accumulation of C99 was a
cause of a defective lysosomal degradation rather than a consequence of increased BACE1 activity or
reduced γ-secretase processing [6]. Indeed, we here found that the overexpression of TFEB leads to
decreased C99 levels in both cellular AD models as well as in the 3xTgAD mouse model. The reduced
C99 accumulation was associated with an increased expression of several lysosomal and autophagic
proteins, including cathepsin B and more importantly cathepsin D, the main proteases responsible for
C99 degradation [6,20]. The lowered levels of C99 could not be due to a higher γ-secretase proteolysis
of C99, since our previous work showed that TFEB had no effect on the expression of any of the
members of the γ-secretase complex (presenilins, Nicatrin, Aph1, and Pen2) [27]. In cellular models
expressing directly the C99 fragment in a wild-type genetic background, TFEB also decreased the
levels of this fragment, indicating that this effect on C99 was due to a direct activation of lysosomal
degradation of C99 and not only due to an enhanced degradation of endocytosed APP. In the 3xTgAD
mouse model, a decrease of C99 was observed both when AAVs were injected into the cerebral ventricle
of newborn mouse brains and when injected stereotaxically into the subiculum of 3-month-old mice.
Taken together, these findings are important considering the numerous recent works suggesting that
C99, independently on Aβ, is a key contributor to early AD pathology. Our data are in agreement
with a very recent study demonstrating that targeting endogenous TFEB pharmacologically using the
curcumin analogue (C1), leads to reduced APP, APP-CTFs, Aβ and tau aggregates in several mouse
models including in the 3xTgAD mouse [42]. The effects of C1 indeed seemed to be directly linked to
TFEB activation, since at least in cultured cells the knockdown of TFEB totally inhibited these beneficial
effects. In agreement with our findings, in the 3xTgAD mouse, C1 treatment had a particularly strong
effect on C99 levels and on the intraneuronal staining detected by 4G8. The work from Song and coll.
also demonstrated that C1 treatment led to reduced cognitive defects in the 3xTgAD mouse. Thus,
altogether our findings confirm that C99 levels are critically controlled by the lysosomal status and
suggest that TFEB is a promising target to prevent the accumulation of this early neurotoxic catabolite.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/5/1204/s1,
Figure S1: Quantification of qPCR analysis of endogenous transcriptional gene expression in dissected hippocampi
from 12 month-old nonTg and 3xTgAD (n = 8 per condition).
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